Department of Pharmacology, Division of Medical Pharmacology, School of Medicine, Showa University, Tokyo, 142-8555, Japan; Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan; Department of Internal Medicine, Division of Neurology, School of Medicine, Showa University, Tokyo, 142-8666, Japan.
Pharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.
Free Radic Biol Med. 2021 Aug 1;171:232-244. doi: 10.1016/j.freeradbiomed.2021.05.019. Epub 2021 May 17.
Excessive accumulation of amyloid β-protein (Aβ) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of Alzheimer's disease (AD). Protofibrils, one of the high-molecular-weight Aβ oligomers (HMW-Aβo), are implicated to be important targets of disease modifying therapy of AD. We previously reported that phenolic compounds such as myricetin inhibit Aβ1-40, Aβ1-42, and α-synuclein aggregations, including their oligomerizations, which may exert protective effects against AD and Parkinson's disease. The purpose of this study was to clarify the detailed mechanism of the protective effect of myricetin against the neurotoxicity of HMW-Aβo in SH-SY5Y cells. To assess the effect of myricetin on HMW-Aβo-induced oxidative stress, we systematically examined the level of membrane oxidative damage by measuring cell membrane lipid peroxidation, membrane fluidity, and cell membrane potential, and the mitochondrial oxidative damage was evaluated by mitochondrial permeability transition (MPT), mitochondrial reactive oxygen species (ROS), and manganese-superoxide dismutase (Mn-SOD), and adenosine triphosphate (ATP) assay in SH-SY5Y cells. Myricetin has been found to increased cell viability by suppression of HMW-Aβo-induced membrane disruption in SH-SY5Y cells, as shown in reducing membrane phospholipid peroxidation and increasing membrane fluidity and membrane resistance. Myricetin has also been found to suppress HMW-Aβo-induced mitochondria dysfunction, as demonstrated in decreasing MPT, Mn-SOD, and ATP generation, raising mitochondrial membrane potential, and increasing mitochondrial-ROS generation. These results suggest that myricetin preventing HMW-Aβo-induced neurotoxicity through multiple antioxidant functions may be developed as a disease-modifying agent against AD.
淀粉样β蛋白(Aβ)的过度积累是导致阿尔茨海默病(AD)发病机制中神经元死亡和磷酸化tau 的主要机制之一。原纤维是高分子量 Aβ 寡聚物(HMW-Aβo)之一,被认为是 AD 疾病修饰治疗的重要靶点。我们之前报道过,类黄酮化合物,如杨梅素,可抑制 Aβ1-40、Aβ1-42 和 α-突触核蛋白的聚集,包括它们的寡聚化,这可能对 AD 和帕金森病发挥保护作用。本研究旨在阐明杨梅素对 SH-SY5Y 细胞中 HMW-Aβo 神经毒性的保护作用的详细机制。为了评估杨梅素对 HMW-Aβo 诱导的氧化应激的影响,我们通过测量细胞膜脂质过氧化、膜流动性和细胞膜电位,系统地检查了细胞膜氧化损伤的水平,通过线粒体通透性转换(MPT)、线粒体活性氧(ROS)和锰超氧化物歧化酶(Mn-SOD)以及 SH-SY5Y 细胞中的三磷酸腺苷(ATP)测定评估了线粒体氧化损伤。研究发现,杨梅素通过抑制 HMW-Aβo 诱导的 SH-SY5Y 细胞中的膜破坏,增加了细胞活力,如降低膜磷脂过氧化和增加膜流动性和膜电阻。研究还发现,杨梅素抑制 HMW-Aβo 诱导的线粒体功能障碍,表现为 MPT、Mn-SOD 和 ATP 生成减少,线粒体膜电位升高,线粒体 ROS 生成增加。这些结果表明,杨梅素通过多种抗氧化功能预防 HMW-Aβo 诱导的神经毒性,可能被开发为治疗 AD 的疾病修饰剂。